X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to conduct early-stage research for novel bi-specific macrophage engagers, ES019, an anti-PD-L1/SIRPα bispecific antibody, and another program.
Lead Product(s): ES019
Therapeutic Area: Oncology Product Name: ES019
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $1,737.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 27, 2023
Details:
ES009 specifically binds to a unique epitope on human LILRB2 and potently blocks LILRB2 binding to multiple ligands, which is investigated for the treatment of cancer.
Lead Product(s): ES009
Therapeutic Area: Oncology Product Name: ES009
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the adenosine and TGF-β pathways, two major immunosuppressive mechanisms in the tumor microenvironment (TME).
Lead Product(s): ES014
Therapeutic Area: Oncology Product Name: ES014
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the CD39-adenosine and TGF-β pathways to synergistically activates T cells for ICB-resistant cancer immunotherapy
Lead Product(s): ES014
Therapeutic Area: Oncology Product Name: ES014
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
ES005, a high affinity anti-LAG3 monoclonal antibody, inhibits the interactions between LAG3 and multiple ligands and enhances anti-tumor activity of T cells in preclinical models.
Lead Product(s): ES005
Therapeutic Area: Oncology Product Name: ES005
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2022
Details:
ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the CD39-adenosine and TGF-β pathways, two major immunosuppressive mechanisms in the tumor microenvironment.
Lead Product(s): ES014
Therapeutic Area: Oncology Product Name: ES014
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
ES104 (asciminib) demonstrated, 42% overall response rate (ORR) based on 10 patients with Partial Responses (PRs), including 9 PRs confirmed by RECIST 1.1 and 1 PR pending confirmation.
Lead Product(s): Asciminib,Paclitaxel
Therapeutic Area: Oncology Product Name: ES104
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
ES002, a potentially best-in-class anti-CD39 antibody, binds to CD39 with sub-nanomolar binding affinity and effectively blocks CD39 ATPase activity. ES002 exhibits a strong efficacy in tumor growth inhibition in vivo.
Lead Product(s): ES002
Therapeutic Area: Oncology Product Name: ES002
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Greater Bay Area Homeland Development Fund
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 13, 2021
Details:
Elpiscience obtains the exclusive development and commercialization rights of TR009 for Greater China across all oncology indications and will lead the clinical development and commercialization to accelerate the path to approval of TR009 in its territory.
Lead Product(s): Asciminib
Therapeutic Area: Oncology Product Name: ABL001
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Trigr
Deal Size: $117.0 million Upfront Cash: $7.0 million
Deal Type: Collaboration January 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
